Skip to main content
Top
Published in: BMC Neurology 1/2015

Open Access 01-12-2015 | Research article

Early statin use in ischemic stroke patients treated with recanalization therapy: retrospective observational study

Authors: Jihoon Kang, Nayoung Kim, Tae Hwan Park, Oh Young Bang, Ji Sung Lee, Juneyoung Lee, Moon-Ku Han, Seong-Ho Park, Philip B. Gorelick, Hee-Joon Bae

Published in: BMC Neurology | Issue 1/2015

Login to get access

Abstract

Background

We aimed to determine whether early statin use following recanalization therapy improves the functional outcome of ischemic stroke.

Methods

Using a prospective stroke registry database, we identified a consecutive 337 patients within 6 h of onset who had symptomatic stenosis or occlusion of major cerebral arteries and received recanalization therapy. Based on commencement of statin therapy, patients were categorized into administration on the first (D1, 13.4 %), second (D2, 20.8 %) and third day or later (D ≥ 3, 15.4 %) after recanalization therapy, and no use (NU, 50.4 %). The primary efficacy outcome was a 3-month modified Rankin Scale score of 0–1, and the secondary outcomes were neurologic improvement, neurologic deterioration and symptomatic hemorrhagic transformation during hospitalization.

Results

Earlier use of statin was associated with a better primary outcome in a dose-response relationship (P for trend = 0.01) independent of premorbid statin use, stroke history, atrial fibrillation, stroke subtype, calendar year, and methods of recanalization therapy. The odds of a better primary outcome increased in D1 compared to NU (adjusted odds ratio, 2.96; 95 % confidence interval, 1.19–7.37). Earlier statin use was significantly associated with less neurologic deterioration and symptomatic hemorrhagic transformation in bivariate analyses but not in multivariable analyses. Interaction analysis revealed that the effect of early statin use was not altered by stroke subtype and recanalization modality (P for interaction = 0.97 and 0.26, respectively).

Conclusion

Early statin use after recanalization therapy in ischemic stroke may improve the likelihood of a better functional outcome without increasing the risk of intracranial hemorrhage.
Appendix
Available only for authorised users
Literature
1.
go back to reference Molina CA, Alvarez-Sabin J. Recanalization and reperfusion therapies for acute ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 1:162–7.CrossRefPubMed Molina CA, Alvarez-Sabin J. Recanalization and reperfusion therapies for acute ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 1:162–7.CrossRefPubMed
2.
go back to reference Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380(9849):1231–40.CrossRefPubMedPubMedCentral Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380(9849):1231–40.CrossRefPubMedPubMedCentral
3.
go back to reference Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849):1241–9.CrossRefPubMed Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849):1241–9.CrossRefPubMed
4.
go back to reference Aronowski J, Strong R, Grotta JC. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab. 1997;17(10):1048–56.CrossRefPubMed Aronowski J, Strong R, Grotta JC. Reperfusion injury: demonstration of brain damage produced by reperfusion after transient focal ischemia in rats. J Cereb Blood Flow Metab. 1997;17(10):1048–56.CrossRefPubMed
5.
go back to reference Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas JF, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36(7):1452–6.CrossRefPubMed Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas JF, et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005;36(7):1452–6.CrossRefPubMed
6.
go back to reference Adams Jr HP, Leira EC, Torner JC, Barnathan E, Padgett L, Effron MB, et al. Treating patients with ‘wake-up’ stroke: the experience of the AbESTT-II trial. Stroke. 2008;39(12):3277–82.CrossRefPubMed Adams Jr HP, Leira EC, Torner JC, Barnathan E, Padgett L, Effron MB, et al. Treating patients with ‘wake-up’ stroke: the experience of the AbESTT-II trial. Stroke. 2008;39(12):3277–82.CrossRefPubMed
7.
go back to reference Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Rother J, et al. Safety of Tirofiban in acute ischemic stroke: the SaTIS trial. Stroke. 2011;42(9):2388–92.CrossRefPubMed Siebler M, Hennerici MG, Schneider D, von Reutern GM, Seitz RJ, Rother J, et al. Safety of Tirofiban in acute ischemic stroke: the SaTIS trial. Stroke. 2011;42(9):2388–92.CrossRefPubMed
8.
go back to reference Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. The Lancet. 2012;380(9843):731–7.CrossRef Zinkstok SM, Roos YB. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial. The Lancet. 2012;380(9843):731–7.CrossRef
9.
go back to reference Cappellari M, Deluca C, Tinazzi M, Tomelleri G, Carletti M, Fiaschi A, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J Neurol Sci. 2011;308(1-2):128–34.CrossRefPubMed Cappellari M, Deluca C, Tinazzi M, Tomelleri G, Carletti M, Fiaschi A, et al. Does statin in the acute phase of ischemic stroke improve outcome after intravenous thrombolysis? A retrospective study. J Neurol Sci. 2011;308(1-2):128–34.CrossRefPubMed
10.
go back to reference Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation. 2005;112(22):3486–94.CrossRefPubMed Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, et al. Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation. 2005;112(22):3486–94.CrossRefPubMed
11.
go back to reference Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91(9):3670–4.CrossRefPubMedPubMedCentral Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 1994;91(9):3670–4.CrossRefPubMedPubMedCentral
12.
go back to reference Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442–9.CrossRefPubMed Laufs U, Gertz K, Huang P, Nickenig G, Bohm M, Dirnagl U, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31(10):2442–9.CrossRefPubMed
13.
go back to reference van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88(1):64–75.CrossRefPubMed van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. Prog Neurobiol. 2009;88(1):64–75.CrossRefPubMed
14.
go back to reference Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, et al. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke. 2006;37(7):1910–2.CrossRefPubMed Wang S, Lee SR, Guo SZ, Kim WJ, Montaner J, Wang X, et al. Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes. Stroke. 2006;37(7):1910–2.CrossRefPubMed
15.
16.
go back to reference Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology. 2012;78(6):421–6.CrossRefPubMed Park JH, Ko Y, Kim WJ, Jang MS, Yang MH, Han MK, et al. Is asymptomatic hemorrhagic transformation really innocuous? Neurology. 2012;78(6):421–6.CrossRefPubMed
17.
go back to reference Noser EA, Shaltoni HM, Hall CE, Alexandrov AV, Garami Z, Cacayorin ED, et al. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke. 2005;36(2):292–6.CrossRefPubMed Noser EA, Shaltoni HM, Hall CE, Alexandrov AV, Garami Z, Cacayorin ED, et al. Aggressive mechanical clot disruption: a safe adjunct to thrombolytic therapy in acute stroke? Stroke. 2005;36(2):292–6.CrossRefPubMed
18.
go back to reference Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41.CrossRefPubMed Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST. trial of org 10172 in acute stroke treatment. Stroke. 1993;24(1):35–41.CrossRefPubMed
19.
go back to reference Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92(6):670–6.CrossRefPubMed Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92(6):670–6.CrossRefPubMed
20.
go back to reference Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–25.CrossRefPubMed Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117–25.CrossRefPubMed
21.
go back to reference Ni Chroinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population stroke study. Stroke. 2011;42(4):1021–9.CrossRefPubMed Ni Chroinin D, Callaly EL, Duggan J, Merwick A, Hannon N, Sheehan O, et al. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population stroke study. Stroke. 2011;42(4):1021–9.CrossRefPubMed
22.
go back to reference Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.CrossRefPubMed Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.CrossRefPubMed
23.
go back to reference Group TNIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef Group TNIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–7.CrossRef
24.
go back to reference Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–82.CrossRefPubMed Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–82.CrossRefPubMed
25.
go back to reference Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110(4):386–91.CrossRefPubMed Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110(4):386–91.CrossRefPubMed
26.
go back to reference Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140(11):857–66.CrossRefPubMed Spencer FA, Allegrone J, Goldberg RJ, Gore JM, Fox KA, Granger CB, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140(11):857–66.CrossRefPubMed
27.
go back to reference Landau WM, Nassief A. Editorial comment--time to burn the TOAST. Stroke. 2005;36(4):902–4.PubMed Landau WM, Nassief A. Editorial comment--time to burn the TOAST. Stroke. 2005;36(4):902–4.PubMed
28.
go back to reference Martinez-Ramirez S, Delgado-Mederos R, Marin R, Suarez-Calvet M, Sainz MP, Alejaldre A, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. J Neurol. 2012;259(1):111–8.CrossRefPubMed Martinez-Ramirez S, Delgado-Mederos R, Marin R, Suarez-Calvet M, Sainz MP, Alejaldre A, et al. Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis. J Neurol. 2012;259(1):111–8.CrossRefPubMed
29.
go back to reference Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 2009;40(5):1729–37.CrossRefPubMed Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 2009;40(5):1729–37.CrossRefPubMed
31.
go back to reference Kumar AD, Boehme AK, Siegler JE, Gillette M, Albright KC, Martin-Schild S. Leukocytosis in patients with neurologic deterioration after acute ischemic stroke is associated with poor outcomes. J Stroke Cerebrovasc Dis. 2013;22(7):e111–7.CrossRefPubMed Kumar AD, Boehme AK, Siegler JE, Gillette M, Albright KC, Martin-Schild S. Leukocytosis in patients with neurologic deterioration after acute ischemic stroke is associated with poor outcomes. J Stroke Cerebrovasc Dis. 2013;22(7):e111–7.CrossRefPubMed
Metadata
Title
Early statin use in ischemic stroke patients treated with recanalization therapy: retrospective observational study
Authors
Jihoon Kang
Nayoung Kim
Tae Hwan Park
Oh Young Bang
Ji Sung Lee
Juneyoung Lee
Moon-Ku Han
Seong-Ho Park
Philip B. Gorelick
Hee-Joon Bae
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2015
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-015-0367-4

Other articles of this Issue 1/2015

BMC Neurology 1/2015 Go to the issue